SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00201214
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This study will determine the pharmacokinetics and safety of intravenous citrulline given to
children undergoing cardiopulmonary bypass for the correction of congenital heart defects.
Name: Citrulline
Description: Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
Type: Drug
Primary Outcomes
Measure: Oxygen index (OI) data to assess increased PVT Time: Measured through the use of continuous mean arterial pressure monitoring
Measure: Qp:Qs ratios to assess increased PVT Time: Measured by blood gases collected 48 hours post-operative
Measure: Increased PVT as measured by a sustained mean pulmonary artery pressure greater than 20 mm Hg for at least 2 hours during the first 24 hours postoperatively Time: Measured through the use of continuous mean arterial pressure monitoring 48 hours post-operative
Purpose: Treatment
Allocation: N/A
Single Group Assignment
There is one SNP
SNPs
1 T1405N
Finally, a genetic single nucleotide polymorphism (SNP) in the rate
limiting urea cycle enzyme (carbamyl phosphate synthetase I [CPSl T1405N]) appeared to affect
postoperative plasma arginine levels and PVT. --- T1405N ---